Alethia BioTherapeutics Inc.

Alethia BioTherapeutics Inc.

July 19, 2005 08:30 ET

Alethia Biotherapeutics, Inc, is Issued a European Patent For Its Target Discovery Technology

MONTREAL, QUEBEC--(CCNMatthews - July 19, 2005) - Alethia BioTherapeutics, Inc., a biotechnology with innovative approaches for the treatment of cancer and related diseases, is pleased to announce the issuance of European Patent No. EP0914470, "Subtractive Amplification".

Alethia's Subtractive Amplification core technology named STAR (Subtractive Transcription-based Amplification of mRNA) when applied to diseased samples, allows the identification of differentially expressed genes specific to that condition, many of which are novel. The method emphasizes the identification of low abundance messenger RNAs allowing a more exhaustive analysis of disease related genes. Alethia generates information on gene expression profiles from minute clinical samples, validates them in diseased tissues, and determines their biological and clinical relevance in cellular disease models as potential therapeutic targets or diagnostic markers.

According to Mario Filion, Ph.D., Chief Operating Officer, "we are extremely pleased to have extended the intellectual property protection for our target discovery platform. This is now the third patent granted after United States and Australia. This technology increases the sensitivity with which disease genes can be discovered compared to current microchip-based approaches. STAR has proven its tremendous potential for identifying novel therapeutic targets."

Alethia's scientists have already identified thousands of disease-related genes using STAR, which were prioritized based on their tissue-specific profiles and finally subjected to biological validation. A patent application for Alethia's validated targets in bone degradation was filed in December 2004.

About Alethia BioTherapeutics:

Established in 2002, Alethia BioTherapeutics is Montreal-based biotechnology company engaged in the discovery and development of therapeutics for the treatment of cancer and cancer-associated complications. Alethia applies its proprietary discovery platform for identification and validation of therapeutic targets in cancer-induced bone loss, ovarian cancer and breast cancer.

Contact Information